Methylene blue-induced Hemolysis in a patient with lidocaine-induced Methemoglobinemia: a case report (2025)

Peer-Reviewed Study · Mehmood M; Almarri FJA · December 26, 2025

Mehmood M et al., 2025-12-26: 2025 case report of severe intravascular haemolysis after intravenous methylene blue given for lidocaine-induced methaemoglobinaemia in a woman with normal G6PD activity.

Methylene blue (MB) is the first-line antidote, but high doses can oxidize hemoglobin and may precipitate hemolysis even in individuals with normal glucose-6-phosphate dehydrogenase (G6PD) activity.

Abstract

Mehmood M et al., 2025-12-26: 2025 case report of severe intravascular haemolysis after intravenous methylene blue given for lidocaine-induced methaemoglobinaemia in a woman with normal G6PD activity. Study type: case report (N=1; 31-year-old woman, normal G6PD). Country: Qatar (Hamad Medical Corporation). Exposure: intravenous methylene blue at another hospital (dose not stated in the abstract) after methemoglobin 13.6% from topical lidocaine; haemoglobin fell to 6.6 g/dL with laboratory haemolysis. Conflicts: none declared. Relevance: the standard 'MB is safe, it is the antidote' line has a documented exception even without G6PD deficiency. Also filed as MTF-31, MTO-40 (claims C10, C5, C6). Study type: case report.